Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.
1/5 보강
OpenAlex 토픽 ·
Pleural and Pulmonary Diseases
Lung Cancer Diagnosis and Treatment
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
APA
Lijing Ye, Lejing Lou, et al. (2026). Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.. BMC cancer. https://doi.org/10.1186/s12885-026-15919-1
MLA
Lijing Ye, et al.. "Efficacy and safety of thoracoscopic photodynamic therapy combined with 5% ethanol-cisplatin intrapleural perfusion in the treatment of malignant pleural effusion in non-small cell lung cancer.." BMC cancer, 2026.
PMID
41928174 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- DnaK supports intracellular persistence of Staphylococcus xylosus and confers mechanical resilience to a human breast cancer cell line.
- Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.
- Fecal metagenome and plasma metabolome analyses reveal changes in gut microbiota composition and plasma metabolites in rats with abemaciclib-induced diarrhea.
- Computational renaissance in herbal medicine: A 20-year bibliometric deciphering of molecular dynamics simulations reshaping traditional Chinese medicine drug discovery.
- Toxic Epidermal Necrolysis in a Patient with Hepatocellular Carcinoma Receiving Pembrolizumab Plus Regorafenib: A Case Report.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
- Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
- A lncRNA and radiomics-based model for predicting the response of non-small cell lung cancer to chemo- and radio-therapy.
- Integration of a glutamine metabolism-based prognostic signature and a synergistic nanotherapeutic strategy targeting metabolic vulnerabilities in prostate cancer.
- Heme oxygenase 1 (HO-1) is a drug target for reversing cisplatin resistance in non-small cell lung cancer.
- A complete pathological response to preoperative chemotherapy in a male patient with primary neuroendocrine breast cancer: a case report.